Business Context and Reporting Period
This Form 8-K Current Report was filed by MiMedx Group, Inc. on April 30, 2009. The filing discloses a private placement financing event that occurred between April 7 and April 30, 2009, involving the sale of debt securities to accredited investors.
Key Financial Metrics
- Proceeds Raised: $1,420,000 aggregate proceeds from the sale of 3% Convertible Senior Secured Promissory Notes.
- Investor Composition: 13 individual accredited investors, including $250,000 from the Chairman/CEO and $150,000 from a director.
- Debt Terms: 3% annual interest rate; 3-year maturity; interest payable in cash at maturity or convertible into common stock.
- Conversion Terms: Convertible into up to 2,840,000 shares of common stock at a price of $0.50 per share.
- Collateral: Secured by a first-priority lien on all assets of MiMedx, Inc. (a wholly-owned subsidiary), excluding the membership interest in SpineMedica LLC.
- Placement Fees: 7% cash fee of proceeds plus 5-year warrants equal to 8% of the convertible shares (exercise price $0.50).
Note: This filing does not provide data on revenue, operating profit, cash flow, margins, or existing liquidity positions.
Material Changes
The primary material change is the creation of a new direct financial obligation and the potential dilution of existing shareholders. The company has incurred $1,420,000 in new debt, which is junior to any bank debt not exceeding $5,000,000. The issuance of warrants and the potential conversion of notes into 2,840,000 shares represents a significant change in the company's capital structure.
Outlook, Risks, and Contingencies
Management Commentary and Risks: The filing includes standard forward-looking statement disclaimers. Management highlights specific risks including the possibility that the Company may not generate revenue or achieve profitability, the need for continued funding, and the risk that products under development may not prove successful.
Contingencies: The Notes contain automatic conversion triggers if the Company sells substantially all assets or equity at a price per share of not less than $0.50. Additionally, the Company has the option to force conversion if the stock price closes at or above $1.50 for 20 consecutive trading days.
Investor Verification Checklist
- Verify the current status of the Company's bank debt to confirm the $5,000,000 senior lien cap mentioned in the filing.
- Confirm the exact number of outstanding shares prior to this offering to calculate the potential dilution from the 2,840,000 convertible shares and associated warrants.
- Review the most recent Form 10-K for details on the Company's cash runway and product development milestones, as this filing indicates a continued need for funding.
- Check the status of the SpineMedica LLC membership interest, which was explicitly excluded from the collateral securing these notes.